Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
Artikel i vetenskaplig tidskrift, 2016

Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8(+) (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older patients and remained significantly predictive of clinical outcome after correction for potential confounders. Presence of CD8(+) T cells with specificity for leukemia-associated antigens identified patients with low relapse risk. Our results point to novel aspects of T cell-mediated immunosurveillance in AML and provide conceivable biomarkers in relapse-preventive immunotherapy.

lymphocytes

acute myeloid leukemia

Cell Biology

immunotherapy

histamine dihydrochloride

Oncology

Immunology and

remission

antigen-specific T cells

maintenance

differentiation

effector

transplantation

responses

interleukin-2

cytotoxic T cells

memory

Författare

Frida Ewald Sander

Göteborgs universitet

Anna Rydström

Göteborgs universitet

Elin Bernson

Göteborgs universitet

Roberta Kiffin

Göteborgs universitet

Rebecca E Riise

Göteborgs universitet

Johan Aurelius

Göteborgs universitet

H. Anderson

Mats Brune

Göteborgs universitet

R. Foa

Kristoffer Hellstrand

Göteborgs universitet

Fredrik B Thorén

Göteborgs universitet

Anna Martner

Göteborgs universitet

Oncotarget

1949-2553 (ISSN)

Vol. 7 7 7586-7596

Ämneskategorier

Klinisk medicin

DOI

10.18632/oncotarget.7210

PubMed

26863635